Medtronic announces cms national coverage analysis for symplicity™ spyral renal denervation system

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure milestone is supported by large public health need and robust, long-term data from the spyral-htn global clinical program galway, ireland , jan. 13, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that the centers for medicare & medicaid services (cms) is opening a national coverage analysis (nca) on renal denervation, a process that will allow the agency to review and develop a national medicare coverage policy for renal denervation procedures for patients with hypertension. this national coverage analysis was initiated by cms in response to medtronic's request to support medicare beneficiary access to the symplicity™ spyral renal denervation (rdn) system, used in the symplicity blood pressure procedure.
MDT Ratings Summary
MDT Quant Ranking